Study of Thyroid Dysfunction in Systemic Lupus Erythematosus by Madeline Vithya, B
 1 
STUDY OF THYROID DYSFUNCTION IN 
SYSTEMIC LUPUS ERYTHEMATOSUS 
 
Dissertation submitted for 
MD Degree (Branch-I)  
General Medicine 
 
 
 
 
 
 
 
The Tamil Nadu Dr.M.G.R. Medical University 
Chennai- 600 032. 
Madurai Medical College, Madurai. 
 
APRIL – 2012 
 
 2 
CERTIFICATE 
 
This is to certify that this dissertation titled “STUDY OF 
THYROID DYSFUNCTION IN SYSTEMIC LUPUS 
ERYTHEMATOSUS ” submitted by DR.B.MADELINE 
VITHYA to the faculty of General Medicine, The Tamil Nadu 
Dr.M.G.R. Medical University, Chennai in partial fulfillment of the 
requirement for the award of MD degree Branch I (General 
Medicine) is a bonafide research work carried out by her under our 
direct supervision and guidance. 
 
 
Dr. Moses K Daniel, MD.,  
Professor and HOD 
Chief   I Medical Unit  
Department of Medicine 
Madurai Medical College 
Madurai. 
 
 
 
 
 3 
DECLARATION 
 
I, Dr.B. MADELINE VITHYA, solemnly declare that the 
dissertation titled „STUDY OF THYROID DYSFUNCTION IN 
SYSTEMIC LUPUS ERYTHEMATOSUS‟ has been prepared by 
me. 
This is submitted to the Tamil Nadu Dr.M.G.R. Medical 
University, Chennai in partial fulfillment of the requirement for the 
award of MD degree Branch I (General Medicine). 
 
 
Place: Madurai 
Date:                                                  Dr. B. MADELINE VITHYA 
 
 
 
 
 
 
 4 
ACKNOWLEDGEMENT 
At the outset, I express my sincere thanks to our Dean for 
permitting me to use the facilities of Madurai Medical College and 
Govt. Rajaji Hospital to conduct this study. 
I will ever remain in gratitude to my chief Dr. Moses K. 
Daniel, MD., Professor and Head of the Department of Medicine, 
not only for guiding me through the study, but also for being my 
mentor and source of inspiration during the period of my 
postgraduate training. He has always guided me by example and by 
valuable words of advice throughout the conduct of the study. 
My sincere thanks to the professor and Head, Department of 
Medical Endocrinology, Dr.J.Sangumani for allowing me to utilize 
the clinical material and for his valuable support and guidance. 
    Knowledge and kindness abounds my beloved teachers         
Dr. S. Vadivel Murugan MD., Dr.V.T. Prem kumar, MD., 
Dr.R.Balajinathan,MD., Dr.M.Natarajan,MD., Dr.G.Bhagya 
lakshmi, MD., Dr.J.Sangumani, MD., Dr. C. Dharmaraj. M.D., 
D.C.H., I owe them a lot and my sincere thanks to them. 
 5 
I express my heartfelt thanks to Associate Professors Dr. 
Jerald Majella, M.D., Dr. Raveendran, M.D., Dr.David Pradeep 
Kumar, MD., and also to Assistant Professors Dr.P.S.Arul Raja 
Murugan MD.DM., Dr. Sreeralaboopathy, M.D.,  Dr.S. 
Sakthimohan, M.D., Dr.P. Manimegalai, M.D., Dr. P.K. Ganesh 
Babu,M.D., Dr.K.Senthil, MD., Dr.S.Peer Mohammed, MD and 
Dr. V.N. Alagavenkatesh MD for their invaluable help throughout 
the period of study. 
My family and friends have stood by me during my times of 
need.  Their help and support have been valuable to the study. 
I would grossly fail in my duty if I fail to mention here of my 
patients who have ungrudgingly borne the pain and discomfort of 
investigations. I cannot but pray for their speedy recovery and place 
this study as a tribute to them and to the numerous others likely 
affected. 
Above all I thank the Lord Almighty for his kindness and 
benevolence. 
 
 
 
 6 
 
CONTENTS 
        PAGE NO. 
1.  INTRODUCTION        1  
2.  REVIEW OF LITERATURE      3 
3.  AIMS AND OBJECTIVES      21 
4.  MATERIALS AND METHODS     22 
5.  RESULTS  AND OBSERVATIONS   26 
6.  DISCUSSION        47 
7.  CONCLUSION        56 
 
APPENDIX 
1.  BIBLIOGRAPHY 
2.  PROFORMA 
3.  MASTER CHART 
4.  ETHICAL COMMITTEE APPROVAL FORM 
 
 
 
 7 
 
ABBREVATIONS 
 
SLE   –  Systemic Lupus Erythematosus 
AITD  –  Autoimmune Thyroid Disease 
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TPO   –  Thyroid Peroxidase  
TPO Ab  –  Thyroid Peroxidase Antibodies 
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      STUDY OF THYROID DYSFUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS  
ABSTRACT 
Background: The higher prevalence of thyroid dysfunction in systemic lupus 
erythematosus patients compared to that of normal population still remains a 
debatable issue. 
Objective: To study the prevalence and pattern of thyroid dysfunction and thyroid 
antibodies in thirty five patients with Systemic Lupus Erythematosus admitted in 
our centre over two years. 
Methods: Thirty five Systemic Lupus Erythematosus patients and twenty healthy 
subjects were evaluated by complete history and physical examination. Patients 
were assessed both clinically and biochemically for thyroid abnormalities. 
Results: The prevalence of thyroid dysfunction (40%) in our study group was 
higher than that of the normal population (5%). Out of which, the prevalence of 
subclinical hypothyroidism (20%) was found to be significantly higher than that of 
the normal population while the prevalence of hyperthyroidism though higher in 
frequency was not significantly different from that of the normal population. 
Overall eleven out of thirty five patients (31.4%) were positive for thyroid 
peroxidase antibodies with about four patients (36.36%) in this subgroup having 
thyroid dysfunction. Among the fourteen patients with thyroid dysfunction, four 
(28.57%) had autoimmune thyroid disease with subclinical hypothyroidism being 
the most common thyroid dysfunction. 
Conclusion: Thyroid dysfunction in our study group was significantly higher with 
majority of patients having subclinical hypothyroidism. The prevalence of thyroid 
autoimmunity was also significantly high suggesting an ongoing slowly destructive 
autoimmune thyroiditis which could later manifest as overt thyroid dysfunction. 
Hence thyroid abnormalities are more common in systemic lupus erythematosus 
which may need regular monitoring to decrease the morbidity and improve the 
quality of life in this subset of patients. 
Keywords: systemic lupus erythematosus, thyroid dysfunction, autoimmunity. 
 8 
1. INTRODUCTION 
        Autoimmune diseases can be divided into organ specific and 
systemic illness. Some of the most common systemic inflammatory 
autoimmune diseases encountered in clinical practice include 
rheumatoid arthritis, systemic lupus erythematosus, 
dermatomyositis, polymyositis and systemic sclerosis. Autoimmune 
thyroid disease is one of the most common manifestations of organ 
specific autoimmune diseases. Whether concomitant organ specific 
and systemic autoimmune diseases occur more often by chance than 
expected is a controversial issue. Hence further studies are 
necessitated to establish this association. 
Systemic lupus erythematosus is a disease of unknown 
etiology in which tissues and cells are damaged by pathological 
autoantibodies and immune complexes. Autoimmune thyroiditis is 
characterized by a slowly progressive asymptomatic phase followed 
later by complete destruction of the thyroid gland manifesting as 
overt hypothyroidism. Even though the demographic group at risk 
for SLE and autoimmune thyroid disease appears to be the same, 
there are several studies and case reports showing greater prevalence 
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of thyroid dysfunction in patients with SLE than the general 
population. Patients with SLE and coexisting thyroid dysfunction 
may escape clinical detection because of the similarities in clinical 
manifestations and the manifestations may be subtle, especially in 
the early stages of the disease. Treatment of the underlying thyroid 
dysfunction helps in improving the quality of life of the patient. 
Hence, although thyroid antibodies and thyroid disease are not 
included in the classification criteria for systemic lupus 
erythematosus, it is reasonable to explore whether patients with SLE 
have a higher prevalence of hypothyroidism and other thyroid 
diseases than that of the normal population. 
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2. REVIEW OF LITERATURE 
2.1 BACKGROUND AND HISTORY: 
      Systemic lupus erythematosus (SLE) is an autoimmune 
disease in which organs and cells undergo damage mediated by 
tissue-binding autoantibodies and immune complexes
1
. It is 
frequently associated with other autoimmune diseases and 
autoantibodies. The most prevalent autoimmune disease found was 
Sjogren syndrome followed by rheumatoid arthritis, autoimmune 
thrombocytopenia and hypothyroidism
2
. The association between 
systemic lupus erythematosus (SLE) and thyroid abnormalities was 
first described in 1961 by White et al
3
 and Hijmans et al
4
, who 
showed that the presence of thyroid disturbances appeared to be 
more frequent in SLE patients than in the general population. Since 
then many series have been reported. The exact prevalence of 
thyroid diseases among South Indian population with SLE still 
remains unknown. 
2.2 AUTOIMMUNITY AND AUTOIMMUNE DISEASE: 
       Autoimmunity leads to recognition of self antigens due to the 
breakdown of one or more of the basic mechanisms regulating 
 11 
immune tolerance
5
. Autoimmune disease is that tissue injury is 
caused by the immunologic reaction of the organism with its own 
tissues. Autoimmunity, on the other hand, refers to the presence of 
antibodies or T lymphocytes that react with self-antigens and does 
not necessarily imply that the development of self-reactivity has 
pathogenic consequences
5
. 
     In patients with systemic autoimmune diseases, the 
pathological lesions are found in multiple diverse organs and tissues 
whereas in organ specific autoimmune disease the manifestations are 
localized. SLE is a disease of protean manifestations that can be 
associated with a variety of autoimmune diseases. Demonstration of 
associated relevant autoimmune manifestations is likely to be 
etiologic in the organ pathology. The occurrence of common 
features of autoimmune diseases and the co association of multiple 
autoimmune diseases in the same individual or family support the 
notion that there may be common genetic factors that predispose to 
autoimmunity
6
. A sex ratio other than 1 in autoimmune disease is 
common, with women representing 75% of autoimmune patients
7
. 
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2.3 SYSTEMIC LUPUS ERYTHEMATOSUS 
    SLE is a chronic, relapsing, inflammatory, and often febrile 
multisystemic disorder of connective tissue, characterized 
principally by involvement of the skin, joints, kidneys, and serosal 
membranes
8
. Ninety percent of patients are women of child-bearing 
years. Interactions between susceptibility genes and environmental 
factors result in abnormal immune responses
1
. The abnormal 
immune response that permits persistence of pathogenic B and T 
cells has multiple components that include processing of increased 
quantities of self antigens by antigen-presenting cells, 
hyperactivation of T and B cells, and failure of multiple regulatory 
networks to interrupt this process
8
. 
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      In the early stages of the disease, the signs may be subtle or 
non-specific. Systemic symptoms particularly fatigue, myalgias and 
arthralgias are present most of the time. SLE occurs 10 times more 
commonly in women than in men. The diagnosis of SLE is based on 
characteristic clinical features and autoantibodies (ACR 1997 
criteria). Survival in patients with SLE is approximately 95% at 5 
years, 90% at 10 years, and 78% at 20 years
 
with treatment
1
. 
 
      The current sine qua non of established lupus is the ANA test 
which is positive in more than 95% of patients at diagnosis. 
Although highly specific, anti-ds-DNA is not necessarily highly 
sensitive for lupus, nor is it always predictive of disease activity. 
Antibodies to Smith are also specific for SLE and do not usually 
correlate with disease activity or clinical manifestations. In addition 
to these, a number of specific epitopes within the nucleus have been 
shown to give rise to positive test results in lupus patients. 
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Courtesy - Harrison’s textbook of internal medicine, seventeenth edition 
  
TABLE 2.1  
AUTOANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS(SLE) 
ANTIBODY PREVALENCE% ANTIGEN CLINICAL 
UTILITY 
ANA 98 Multiple nuclear Best screening test 
Anti – ds DNA 70 DNA(double 
stranded) 
High titers are 
specific. Correlates 
with disease activity 
Anti – Smith 25 Protein complexed 
to U1 RNA 
Specific for SLE 
Anti – RNP 40 Protein complexed 
to U1 RNA 
(gamma) 
Overlap syndromes 
Anti – Ro(SS-A) 30 Protein complexed 
to hY RNA (60 
kDa) 
Siccasyndrome. 
Predisposes to 
SCLE , neonatal 
lupus 
Anti – La(SS-B) 10 Protein complexed 
to hY RNA (47 
kDa) 
Decreased risk for 
nephritis 
Antihistone 70 Histones associated 
with DNA 
Drug induced lupus 
Antiphospholipid 50 Phospholipids, 
prothrombin 
ELISA for 
cardiolipin, beta2G1 
and DRVVT 
Antierythrocyte 60 Erythrocyte 
membrane 
Overt hemolysis 
Antiplatelet 30 Surface and altered 
cytoplasmic 
antigens on 
platelets 
Thrombocytopenia 
 
Antineuronal 60 Neuronal and 
lymphocyte surface 
antigens 
Active CNS Lupus 
(CSF) 
Antiribosomal P 20 Protein in 
ribosomes 
Active CNS Lupus 
(serum) 
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2.4  SLE AND OTHER AUTOIMMUNE DISEASES 
       The association of systemic lupus erythematosus (SLE) with 
other autoimmune diseases (AID) is well established
4
. Interestingly, 
J E McDonagh, D A Isenberg et al reported that clustering of both 
systemic and organ specific autoimmune diseases (AID) occurs in 
patients with SLE with almost a third of patients having at least one 
other AID (30%)
2
. The association of additional AID in SLE patients 
is likely to be multifactorial with interplay of ubiquitous 
environmental and hormonal factors in genetically predisposed 
people. Hence, all patients with SLE should be screened for the 
possible development of a second AID during follow up and regular 
serological testing may be advantageous. 
      According to a study by S A Chambers, S C Charman et al, 
out of 401 patients with SLE, there were 131 patients (33% of the 
cohort) who had at least one other AID, including 100 (25%) with 
one other AID, 26 (7%) with two and 5 (1%) with three AID in 
addition to SLE
9
. Chronology of AID development in patients with 
SLE differs depending on the disease involved. Those patients whose 
additional AID was autoimmune thyroid disease were more likely to 
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develop this before SLE (75%) compared to 7% in the same year as 
diagnosis of SLE and 18 % after SLE
9
.  
      The tendency for familial clustering of autoimmune diseases is 
well known. Studies of families with multiple autoimmune diseases 
have led to interesting discoveries that genetic factor that could play 
a vital role in the explanation of this phenomenon. One such 
discovery is the recognition of a single nucleotide polymorphism 
(rs2476601, encoding R620W) in the intracellular tyrosine 
phosphatase (PTPN22) that could confer risk of four separate 
autoimmune phenotypes (type 1 diabetes, rheumatoid arthritis, SLE 
and Hashimoto’s thyroiditis) in the families that were studied10. This 
finding suggests a common underlying etiologic pathway for some 
autoimmune disorders. 
      In conclusion, patients with SLE might present with a variety 
of other AID and this could have an impact on damage and 
mortality
9
. Strategies for managing lupus patients who have 
additional AID should include close monitoring for the adverse 
effects associated with the prolonged use of higher doses of 
corticosteroids and other immunosuppressants that might be required 
to treat the combined autoimmune disorders. 
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2.5 AUTOIMMUNE THYROID DISEASE (AITD) 
     AITD is the most common organ specific autoimmune disorder 
comprising of Graves disease, Hashimoto’s thyroiditis, atrophic 
thyroiditis, post partum thyroiditis, silent thyroiditis and thyroid 
associated ophthalmopathy
11
. It is a known fact that there is a higher 
prevalence of AITD in patients with other autoimmune diseases. 
These disorders share antibodies against thyroglobulin (Tg Ab), 
thyroid peroxidase (TPO Ag) and TSH receptor (TSH-R Ab) besides 
some other minor antigens
12
. Females are found to be commonly 
affected and this is due to sex steroid effects on the immune 
response. An X chromosome–related genetic factor may also 
contribute, which may account for the high frequency of 
autoimmune hypothyroidism in Turner syndrome. The concordance 
rate in monozygotic twins is 33-55% as compared to less than 5% in 
dizygotic twins. Autoantibody status, ultrasonographic features and 
fine needle aspiration biopsy findings are very useful in the 
diagnosis of AITD
13
. 
     Patients may present with a goiter (Hashimoto's thyroiditis) or at 
the later stages of the disease (atrophic thyroiditis) goiter may not be 
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present. The autoimmune process gradually reduces thyroid function 
leading to a phase of compensation when normal thyroid hormone 
levels are maintained by a rise in TSH called subclinical 
hypothyroidism
14
. As the disease progresses, unbound T4 levels fall 
and TSH levels rise further leading to clinical or overt 
hypothyroidism. The mean annual incidence rate is up to 4 per 1000 
women and 1 per 1000 men. Japanese population is more commonly 
affected probably because of genetic factors and chronic exposure to 
a high-iodine diet. The mean age at diagnosis is 60 years, and the 
prevalence of overt hypothyroidism increases with age
14
.  
      HLA-DR polymorphisms are the best documented genetic risk 
factors for autoimmune hypothyroidism, especially HLA-DR3, -
DR4, and -DR5 in Caucasians. A weak association also exists 
between polymorphisms in CTLA-4, a T cell–regulatory gene, and 
autoimmune hypothyroidism. These genetic associations are not 
unique to autoimmune thyroid disease being also found in other 
autoimmune diseases. The onset is usually insidious, and the patient 
may become aware of symptoms only when euthyroidism is 
restored. Patients with Hashimoto's thyroiditis in the early stages 
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may be asymptomatic except for the presence of a goiter. On the 
contrary, patients with atrophic thyroiditis or the late stage of 
Hashimoto's thyroiditis may present with symptoms and signs of 
hypothyroidism
14
.  
      Therefore, estimation of thyroid autoantibodies and TSH, T 3 ,T 4 
are useful in the diagnosis of AITD
13
. Once clinical or subclinical 
hypothyroidism is confirmed, the etiology can be easily established 
by demonstrating the presence of TPO antibodies, which are present 
in >90% of patients with autoimmune hypothyroidism
14
.Fine needle 
aspiration biopsy is very much useful in the diagnosis of AITD
12
. 
Thyroid ultrasonography could be useful for diagnosis especially in 
children where antibodies and biopsy are not feasible
15
.  
     The prevalence rates according to several studies show that 
subclinical hypothyroidism is found in 6–8% of women and 3% of 
men. The annual risk of developing clinical hypothyroidism is about 
4% when subclinical hypothyroidism is associated with positive 
TPO antibodies. On follow up, it is important to confirm that any 
elevation of TSH is sustained over a 3-month period in order to 
make future therapeutic decisions. As long as excessive treatment is 
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avoided, there is no risk in correcting a slightly increased TSH due 
to increased risk of progression to overt hypothyroidism. Treatment 
is administered by starting with a low dose of levothyroxine (25–50 
g/d) with the goal of normalizing TSH
14
. 
2.6 THYROID AUTOIMMUNITY–THYROID SPECIFIC 
AUTOANTIBODIES 
     Antibodies against thyroid specific antigens, anti-thyroid 
peroxidase (TPO), thyroglobulin (Tg), and TSH receptors are useful 
in the diagnosis of autoimmune thyroid disorders. 
      Thyroid peroxidase enzyme (TPO) was recently discovered to be 
the principal antigen in the thyroid microsomes.TPO is an useful 
enzyme in the biosynthesis of thyroid hormones and catalyses the 
oxidation of an iodide ion and the coupling of iodotyrosyl residues 
of Tg. Patients with Grave’s disease, Hashimoto’s, atrophic 
thyroiditis or post-partum thyroiditis have all been known to be TPO 
Ab positive. Thyroid peroxidase antibodies have been implicated to 
be a cytotoxic agent associated with the destructive process involved 
in the hypothyroidism seen with autoimmune thyroiditis. Several 
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studies have indicated that these antibodies usually precede the 
development of thyroid dysfunction. Future studies may even 
indicate that it can be used as a prognostic indicator for thyroid 
dysfunction. The paradoxical absence of TPOAb in some patients 
with unequivocal TSH abnormalities likely reflects the suboptimal 
sensitivity or specificity of current TPOAb tests or non autoimmune 
thyroid failure (atrophic thyroiditis)
16
.  
      TPOAb is also detected at higher levels in patients with non-
thyroid autoimmune diseases such as type 1diabetes and pernicious 
anemia. Euthyroid patients with detectable TPOAb are at an 
increased risk for development of hypothyroidism. Detectable level 
of TPOAb typically precedes the development of an elevated TSH 
and is therefore considered to be a risk factor for hypothyroidism. 
Apart from hypothyroidism, the presence of TPO Ab is associated 
with reproductive complications such as miscarriage, infertility, IVF 
failure, fetal death, pre-eclampsia, preterm delivery and post-partum 
thyroiditis. Depression is also associated with increased levels of 
TPOAb. The enhanced sensitivity and specificity of the TPO 
immunoassay methods make them a more cost-effective option over 
the older semi-quantitative AMA agglutination tests, since they 
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obviate the need for additional TgAb measurements in the routine 
diagnosis of autoimmune thyroid disorders
16
. 
      Thyroglobulin autoantibodies (TgAb) are also found in 
autoimmune thyroid conditions, usually in association with TPOAb. 
However, the recent NHANES III study found that only 3 % of 
subjects with no risk factors for thyroid disease had isolated 
elevation of thyroglobulin antibodies and there was no association 
with TSH abnormalities. Therefore the clinical significance of an 
isolated TgAb abnormality remains to be established. This study 
suggests that it is unnecessary to measure both TPOAb and TgAb for 
a routine evaluation of thyroid autoimmunity
16
. TSH Receptor 
antibodies are useful in the differential diagnosis of hyperthyroidism, 
the prediction of fetal and neonatal thyroid dysfunction due to 
transplacental passage of maternal TRAb and prediction of the 
course of Graves’ disease treated with anti thyroid drugs16 but not for 
the diagnosis of autoimmune thyroiditis. 
     The prevalence of anti TPO antibodies and TgAb is high in 
SLE patients than in controls, although their inhibitory activity is 
less than in thyroid diseases
17
.On analyzing several studies, 
antibodies to other thyroid antigens have been only rarely assayed in 
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SLE. Thyroid stimulating immunoglobulin / thyroid binding 
inhibitory immunoglobulin, both of which target the TSH receptor 
have been found in the sera of 5 and 10 of 28 SLE patients
18
. Hence 
the routine testing for these antibodies are not necessary.    
2.7 AITD AND SYSTEMIC AUTOIMMUNE DISORDERS  
Autoimmune hypothyroidism may be associated with signs or 
symptoms of other autoimmune diseases, particularly vitiligo, 
pernicious anemia, Addison's disease, alopecia areata, and type 1 
diabetes mellitus. Less-common associations include celiac disease, 
dermatitis herpetiformis, chronic active hepatitis, rheumatoid 
arthritis, systemic lupus erythematosus (SLE), and Sjögren’s 
syndrome. The association of chronic autoimmune thyroiditis with 
rheumatic diseases such as systemic lupus erythematosus (SLE), 
Sjögren’s syndrome (SS), systemic sclerosis, rheumatoid arthritis 
(RA) is well recognized
4,17,19-22
.This result suggests extensive genetic 
sharing among these autoimmune diseases. Many rheumatic 
manifestations such as fibrositis, myositis, myalgias, carpal tunnel 
syndrome, joint stiffness, and joint effusion have been described in 
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association with chronic autoimmune thyroiditis and these symptoms 
seem to be due to hypothyroidism which is frequently seen
23,24
. 
2.8  THYROID DISEASES IN SYTEMIC LUPUS 
ERYTHEMATOSUS 
     A number of studies have suggested that thyroid disease is more 
common in SLE than in the general population, but there is 
disagreement as to whether both hypothyroidism and 
hyperthyroidism are more common or whether this finding is 
restricted to hypothyroidism alone. Both antithyroglobulin and 
antimicrosomal antibodies have been found with greater frequency 
in SLE than in the general population, even in lupus patients who do 
not have clinical thyroid disease
25,26
. It is still a subject of discussion 
as to whether SLE is an independent risk factor for these thyroid 
abnormalities or whether this is a coincidental finding because the 
group most at risk for SLE, young to middle aged women, is 
precisely the same group most at risk for autoimmune thyroid 
disease
27
. 
        Analyzing the frequency of AID by ethnic group, it was found 
that among the South Asians, 13 (76.5%) had one AID, 3 (17.6%) 
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had two and 1 (5.9%) had three other AID. In South Asians, 
autoimmune hypothyroidism was the most common other AID 
(27.3%) followed by Sjogrens syndrome (22.7%), antiphospholipid 
syndrome and myositis
9
. Subgroup analysis revealed that a higher 
proportion of South Asians developed thyroid disease compared to 
the black patients
9
. Attia and colleagues examined the occurrence of 
other AID in 60 Arab and Asian patients from the Indian 
subcontinent with SLE under follow-up for 12 years in Abu Dhabi 
and reported similar findings
28
.The R620W polymorphism of the 
PTPN22 gene appears to be a risk factor for concurrent autoimmune 
thyroid disease and SLE
29
. The locus 5q14.3-15 harbors a 
susceptibility gene which may be shared by SLE and AITD
49
.Also 
stratifying SLE pedigrees by the presence of other autoimmune 
disorders may facilitate the discovery of other genes related to SLE. 
    In summary it is clear that SLE and other AID coexist 
commonly in individual patients. It is important to be aware of this, 
because symptoms of different AID can often be very similar, which 
means that diagnosis of a second AID could potentially be delayed 
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by wrongful attribution of symptoms to the first. Hence the need for 
additional testing of associated thyroid dysfunction. 
2.9 PREVALENCE OF AITD IN SYSTEMIC LUPUS 
ERYTHEMATOSUS 
TABLE 2.2: Studies of the prevalence of hyperthyroid and 
hypothyroid disease in SLE 
STUDY NO : 
SLE 
NO: HYPO 
THYROID 
% OF HYPO 
THYROIDISM 
NO: HYPER 
THYROIDISM 
% OF HYPER 
THYROIDISM 
Bryon et al
31. 
64 3 4.7 7 10.9 
Weetman et al
32. 
41 10 24 0 0 
Chang et al
33. 
45 2 4.4 1 2.2 
Boey  et al
34. 
129 5 3.9 1 0.8 
Vianna  et al
35. 
100 6 6 2 2 
Eberhad  et al
36. 
35 4 11.4 0 0 
Miller et al
37. 
332 22 6.6 3 0.9 
Kohner  et al
38 
175 9 5 0 0 
Rodrique et al
39 
93 -- -- 6 6.5 
 
Two studies have suggested that there is no statistically 
significant difference in the prevalence of thyroid disease in SLE 
compared with age and sex matched controls, despite a higher 
prevalence of antithyroglobulin antibodies being found in the SLE 
group
3,5
. Because only a few studies have examined this issue, and 
numbers were small, the question as to whether lupus patients have 
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an excess of thyroid disease over and above that of age and sex 
matched controls remains debatable. 
     Despite this, the reported prevalence of autoimmune thyroid 
disease (3.9–24%) and antithyroid antibodies (11–51%) in SLE 
varies considerably from different studies. High risk patients 
especially females, raised TSH, positive TPO antibodies should have 
thyroid function follow up and should be given thyroid treatment in 
due course. Therefore it is recommended to perform intermittent 
biochemical screening of thyroid function in patients with SLE, 
particularly if they are known to have thyroid antibodies, to identify 
clinical/subclinical thyroid disease. 
   
 
 
 
 
 
 28 
 
 
 
3. AIM AND OBJECTIVES 
 
The aim of the study were as follows 
1.  To study the prevalence and pattern of thyroid dysfunction in 
Systemic lupus erythematosus patients. 
2.  To determine the prevalence of thyroid autoimmunity among 
them. 
3.  To correlate thyroid autoimmunity with thyroid dysfunction. 
4.  To correlate any age, gender and disease duration difference        
among SLE patients with and without thyroid dysfunction. 
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4. MATERIALS AND METHODS. 
STUDY DESIGN 
Cross sectional observational study to analyze the prevalence 
of thyroid disorders and thyroid autoimmunity among Systemic 
lupus erythematosus patients. 
SETTING 
Collaborating departments: 
Department of Medicine/ Department of Endocrinology/ 
Division of Rheumatology, Government Rajaji Hospital, Madurai 
Medical College, Madurai. 
APPROVAL 
The study was approved by the ethical committee of 
Government Rajaji Hospital, Madurai Medical College. 
STUDY POPULATION 
Systemic lupus erythematosus patients who attended the 
Department of Rheumatology and Department of Medicine from 
April 2010 to September 2011 were enrolled in the study along with 
appropriate age and sex matched controls. Thirty five patients 
among them satisfied criteria for inclusion into the study. Twenty 
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age and sex matched people from normal population were taken as 
controls. 
No. of patients enrolled  :  35 
No. of controls   :  20 
INCLUSION CRITERIA 
Established cases of SLE as per the American college of 
Rheumatology criteria 1982(revised in 1997) 
EXCLUSION CRITERIA 
1.  Pregnancy 
2.  Evidence of other autoimmune diseases like Addison’s 
disease, vitiligo, autoimmune hepatitis, rheumatoid arthritis. 
3.  Chronic kidney disease 
4.  Past history of thyroid surgery or radioiodine therapy 
5.  Critically ill patients. 
6.  Patients taking drugs which alter thyroid function tests. 
CONSENT 
Patients were informed about the details of the test performed 
and blood sample collected with consent. 
SAMPLE COLLECTION 
Venous blood sample was collected. After serum separation, 
sample was sent for analysis. 
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METHOD OF TESTING 
T3 , T4 , TSH – chemiluminescence immunoassay(CLIA) 
TPO – Enzyme chemiluminescence immunoassay (ECLIA) 
NORMAL RANGE 
T3 – 80 – 200 ng/dl 
T4 – 4.6 – 13 µg/dl 
TSH 3
rd
 generation( hs TSH) – 0.27 – 4.20 mIu/mL 
Anti TPO Ab – 0-34 IU/L 
INTERPRETATION OF RESULTS 
NO T3 T4 TSH ANTI 
TPO Ab 
INTERPRETATION 
1 N N N N Euthyroidism 
2 N N Increased (up 
to 10 mIu/L) 
N Subclinical hypothyroidism 
3 Decreased Decreased 
 
Increased (>10 
mIu/L) 
N Overt hypothyroidism 
4 N N Decreased 
 
N Subclinical hyperthyroidism 
5 Increased Increased Decreased N Hyperthyroidism 
6 Decreased 
 
N/ Decreased Variable 
 
N Non thyroidal illness(ESS) 
7 Variable Variable Variable Positive Thyroid autoimmunity 
8 Hypothyroidism or hyperthyroidism with positive anti 
TPO Ab 
Autoimmune thyroid disease 
 
 
 
 32 
STATISTICAL ANALYSIS 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2010) 
developed by Centre for Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, 
standard deviations, chi square and 
 
'p'  values were calculated. 
Kruskul Wallis chi-square  test was used to test the significance of 
difference between quantitative variables and Yate’s chi square test 
for qualitative variables. A 'p' value less than 0.05 is taken to denote 
significant relationship. 
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5. RESULTS AND ANALYSIS OF OBSERVED DATA 
Total number of patients enrolled in the study : 35 
Number of males   :  3 
Number of females:  32 
Number of patients with thyroid dysfunction  : 14 out of 35 (40%) 
1. No of subclinical hypothyroid patients     :   7 out of 35 (20%) 
2. No of overt hypothyroid patients              :   nil 
3. No of hyperthyroid patients                      :   4 out of 35(11.4%) 
4. No of patients with ESS                            :  3 out of 35(8.6%) 
Number of patients with positive  
Anti TPO Antibodies    :  11 out of 35 (31.4%) 
1. Euthyroidism                            :  7 out of 11(63.63%) 
2. Subclinical hypothyroidism    :  3 out of 11(27.27%) 
3. Hyperthyroidism                       :  1 out of 11(9.09%) 
Number of patients with thyroid dysfunction and positive Anti TPO 
Antibodies: 4 out of 35 (11.42%) 
1. Subclinical hypothyroidism    :  3 out of 4 (75%) 
2. Hyperthyroidism                      :  1 out of 4 (25%) 
Prevalence of autoimmune thyroid disease in patients with thyroid 
autoimmunity                          :  4 out of 11 (36.36%) 
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Total number of controls enrolled in the study  :  20 
Number of males          :  3 
Number of females         :  17 
Number of patients with thyroid dysfunction     : 1 out of 20 (5%) 
Number of patients with thyroid                          : 1 out of 20 (5%) 
Autoimmunity 
Number of patients with AITD                             :  Nil 
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ANALYSIS OF OBSERVED DATA 
PROFILE OF CASES STUDIED: 
TABLE 1 
AGE DISTRIBUTION OF STUDY AND CONTROL GROUP 
Age group Study group Control group 
No % No % 
< 20 years 5 14.3 5 25 
20-29 years 20 57.1 5 25 
30-39 years 8 22.9 9 45 
40 & Above  2 5.7 1 5 
Total 35 100 20 100 
Range 16-52 years 15-40 years 
Mean 26.3 years 27.7 years 
SD 8.0 years 7.9 years 
‘p’ 0.3352 
Not significant 
 
 The age of the study group was 26.3 +8 years and the control group 
was 27.7 +7.9 years. The difference is not statistically significant (p = 
0.3352). 
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CHART 1 :  MEAN AGE DISTRIBUTION OF THE STUDY 
AND CONTROL GROUP 
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TABLE 2  
SEX DISTRIBUTION OF STUDY GROUP AND  
CONTROL GROUP 
 
Sex Study group Control group 
No % No % 
Male 3 8.6 3 15 
Female 32 91.4 17 85 
Total 35 100 20 100 
‘p’ 0.3769 
Not significant 
 
 91.4 % of the study group and 85% of the control group were 
females. The difference in the sex composition is not significant (p > 
0.05). 
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CHART 2: MEAN SEX DISTRIBUTION OF STUDY AND 
CONTROL GROUP 
 
 
 
 
 
 
 
 
 
 39 
 
        
     TABLE - 3 
THYROID DYSFUNCTION IN STUDY AND  
CONTROL GROUP 
Interpretation Study group Control group 
No % No % 
Euthyroid 
Non thyroidal illness 
21 
3 
60 
8.6 
19 
1 
95 
5 
Subclinical 
hypothyroidism 
Hyperthyroidism 
7 
4 
20 
11.4 
 
- 
- 
 
- 
- 
 
Total 35 100 20 100 
‘p’ 0.0051 
Significant 
 
Thyroid dysfunction was present in 40% of the study cases and in 
5% of the control cases and the difference is found to be statistically 
significant (p<0.0051) 
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CHART 3   COMPARISON OF THYROID STATUS IN 
STUDY AND CONTROL POPULATION. 
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CHART 4: THYROID STATUS OF PATIENT POPULATION 
IN PERCENTAGE 
 
 
 
 
 
 
 
 
 
 42 
 
 
TABLE 4 
THYROID STATUS IN RELATION TO AGE 
 
 
Thyroid 
dysfunction 
Age ( in years) 
Mean SD 
Yes 24.2 6.4 
No 27.2 8.5 
‘p’ 0.2772 
Not significant 
 
 There was no significant relationship between thyroid dysfunction 
and age of the patient. 
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CHART 5: THYROID STATUS IN RELATION TO AGE 
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TABLE 5 
THYROID DYSFUNCTION IN RELATION TO SEX 
 
 
Sex 
 
No .of 
cases 
Thyroid dysfunction 
Yes No 
No % No % 
Male 3 2 66.66 1 33.33 
Female 32 11 34.37 21 65.62 
‘p’ 0.227 
Not significant 
 
 Sex of the patient and incidence of thyroid disease were not 
significantly related (p > 0.05). 
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CHART 6: THYROID DISEASE IN RELATION TO SEX 
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TABLE 6 
THYROID STATUS IN RELATION TO  
DURATION OF DISEASE 
 
 
Thyroid 
dysfunction 
Duration in years 
 
Mean 
 
SD 
Yes 1.21 1.86 
No 1.49 2.18 
‘p’ 0.4383 
Not significant 
 
 Duration of illness did not have any significant relationship with 
incidence of thyroid dysfunction. 
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CHART 7: THYROID STATUS IN RELATION TO 
DURATION OF DISEASE 
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TABLE 7 
THYROID STATUS IN RELATION TO 
SYMPTOMATOLOGY 
 
Symptoms No. of 
cases 
Thyroid dysfunction 
Yes No 
No % No % 
Present 16 6 37.5 10 62.5 
Absent 19 8 42.10 11 57.89 
‘p’ 0.7304 
Not significant 
 
 Presence or absence of symptoms did not significantly affect 
incidence of thyroid dysfunction ( p = 0.7304). 
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TABLE 8 
SUBCLINICAL HYPOTHYROIDISM IN STUDY AND 
CONTROL POPULATION 
 
SUBCLINICAL 
HYPOTHYROIDISM 
Study group Control group 
No % No % 
Yes 7 20 0 0 
No 28 80 20 100 
‘p’ 0.0331 
Significant 
 
Subclinical hypothyroidism was present in 20% of study cases and 
none of control cases. This difference is statistically significant (p = 
0.0331). 
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CHART 8: SUBCLINICAL HYPOTHYROIDISM IN STUDY 
AND CONTROL POPULATION 
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         TABLE 9 
HYPERTHYROIDISM IN STUDY AND CONTROL 
POPULATION 
 
HYPER 
THYROIDISM 
Study group Control group 
No % No % 
Yes 4 11.42 0 0 
No 31 88.57 20 100 
‘p’ 0.1535 
Not Significant 
 
Hyperthyroidism was present in 11.42% of study cases and none of 
control cases. This difference is not statistically significant (p = 0.1535). 
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CHART 9  : HYPERTHYROIDISM IN STUDY AND 
CONTROL POPULATION 
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                                                        TABLE 10 
THYROID AUTOIMMUNITY IN STUDY AND CONTROL 
POPULATION 
 
Thyroid 
Autoimmunity 
Study group Control group 
No % No % 
Yes 11 31.4 1 5 
No 24 68.6 19 95 
‘p’ 0.0209 
Significant 
 
 Thyroid autoimmunity which is defined as the presence of Anti 
TPO Antibodies irrespective of presence of thyroid dysfunction was 
present in 31.4% of study cases and 5% of control cases. This difference 
is statistically significant (p = 0.0209). 
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CHART 10: THYROID AUTOIMMUNITY IN STUDY AND 
CONTROL POPULATION 
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TABLE 11 
THYROID AUTOIMMUNITY IN RELATION TO AGE 
 
THYROID 
AUTOIMMUNITY 
Age ( in years) 
Mean SD 
Yes 23.0 3.9 
No 27.8 8.9 
‘p’ 0.1541 
Not significant 
 
 There was no significant relationship between autoimmune 
thyroiditis and age of the patient. 
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CHART 11: THYROID AUTOIMMUNITY IN RELATION TO 
AGE 
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TABLE 12 
THYROID AUTOIMMUNITY IN RELATION TO SEX 
 
Sex No. of 
cases 
THYROID 
AUTOIMMUNITY 
Yes No 
No % No % 
Male 3 - - 3 100 
Female 32 11 34.4 21 65.6 
‘p’ 0.3092 
Not significant 
 
 Sex of the patient and incidence of autoimmune thyroiditis were 
not significantly related (p > 0.05). 
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CHART 12: THYROID AUTOIMMUNITY IN RELATION TO 
SEX 
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                                            TABLE 13 
THYROID AUTOIMMUNITY IN RELATION TO 
DURATION OF DISEASE 
 
THYROID 
AUTOIMMUNITY 
Duration in years 
Mean SD 
Yes 0.9 1.42 
No 1.63 2.28 
‘p’ 0.9425 
Not significant 
 
 Duration of illness did not have any significant relationship with 
incidence of autoimmune thyroiditis. 
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CHART 13: THYROID AUTOIMMUNITY IN RELATION TO 
DURATION OF DISEASE 
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TABLE 14 
THYROID AUTOIMMUNITY IN RELATION TO 
SYMPTOMATOLOGY 
 
Symptoms No. of 
cases 
THYROID 
AUTOIMMUNITY 
Yes No 
No % No % 
Present 16 6 37.5 10 62.5 
Absent 19 5 26.3 14 73.7 
‘p’ 0.7304 
Not significant 
 
 Presence or absence of symptoms did not significantly affect the 
incidence of thyroid autoimmunity (p = 0.7304). 
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TABLE 15 
CORRELATION BETWEEN THYROID AUTOIMMUNITY 
AND THYROID STATUS 
 
 
Interpretation 
No. of 
cases 
Thyroid autoimmunity 
Yes No 
No % No % 
Euthyroidism 
Non thyroidal illness 
21 
3 
7 
- 
33.3 
- 
14 
3 
66.7 
100 
Subclinical 
hypothyroidism 
Hyperthyroidism 
 
7 
4 
 
3 
1 
 
42.9 
25 
 
4 
3 
 
57.1 
75 
Total 35 11 31.4 24 68.6 
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CHART 14: CORRELATION BETWEEN THYROID 
AUTOIMMUNITY AND THYROID STATUS 
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CHART  15 :THYROID AUTOIMMUNITY AND THYROID 
DYSFUNCTION 
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TABLE 16 
AUTOIMMUNE THYROID DISEASE IN STUDY AND 
CONTROL POPULATION 
Auto Immune 
Thyroid Disease 
Study group Control group 
No % No % 
Yes 4 11.42 - - 
No 31 88.57 20 100 
‘p’ 0.1535 
Not Significant 
 
Autoimmune thyroid disease defined by the presence of 
thyroid dysfunction and positive Anti TPO Antibodies was present 
in 11.42% of the study population as compared to none in the control 
population. Although there was a higher frequency of AITD in study 
population as compared to control population, the p value failed to 
meet statistical significance. 
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CHART 16: PREVALENCE OF AUTOIMMUNE THYROID 
DISEASE IN STUDY AND CONTROL GROUP 
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TABLE 17 
AUTOIMMUNE THYROID DISEASE AMONG PATIENTS 
WITH THYROID DYSFUNCTION 
 
THYROID 
DYSFUNCTION 
No. of 
cases 
Thyroid autoimmunity 
Yes No 
No % No % 
Subclinical 
hypothyroidism 
Hyperthyroidism 
Non thyroidal illness 
 
7 
4 
3 
 
3 
1 
- 
 
42.85 
25 
- 
 
4 
3 
3 
 
57.1 
75 
100 
Total 14 4 28.57 10 71.42 
 
Among patients with thyroid dysfunction, 28.57 %( 4 out of 
14) patients were found to have TPO positivity i.e. autoimmune 
thyroid disease. Out of these 4 patients, 75 %( 3 out of 4) had 
subclinical hypothyroidism and 25 %(1 out of 4) had 
hyperthyroidism. 
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CHART 17: AUTOIMMUNE THYROID DISEASE AMONG 
PATIENTS WITH THYROID DYSFUNCTION 
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CHART 18: THYROID DYSFUNCTION IN AUTOIMMUNE 
THYROID DISEASE 
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OBSERVATIONS 
      Majority of the patients were from in and around Madurai. The 
mean age of the study group was 26.3 +8 years and the control group 
was 27.7 +7.9 years. Majority of the patient population were 
females. 91.4 % of the study group and 85% of the control group 
were females. Majority of the patients presented with easy 
fatigability and constitutional symptoms like arthralgias and 
myalgias. About 45.71% of patients presented with symptomatology 
suggestive of thyroid dysfunction although there might have been 
some overlap between rheumatic manifestations. Though the actual 
numbers are high, there is no statistically significant difference in 
age, sex and symptomatology, duration of SLE between those with 
and without thyroid dysfunction. 
     About 40% of patients from our study group had thyroid 
dysfunction (20% had subclinical hypothyroidism, 11.4% had 
hyperthyroidism and 8.6% non thyroidal illness) compared to 5% 
among the controls. The higher frequency of thyroid dysfunction in 
SLE population when compared to the control group (40 % vs. 5 %) 
was found to be statistically significant (p=0.0051). The prevalence 
of subclinical hypothyroidism (20%) in our study group was higher 
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than in the control population and met statistical significance 
(p=0.0331), while that of hyperthyroidism (11.42%) though higher 
in prevalence failed to meet statistical significance (p=0.1535).The 
prevalence of thyroid disorders among controls was however found 
to be of a lesser degree compared to other studies probably due to a 
smaller sample size
50
. 
   About 31.4% of patients from study group had thyroid 
autoimmunity (11 out of 35) compared to 5% among the controls. 
Hence there is a higher prevalence of Anti TPO Ab among SLE 
patients when compared to controls with statistical significance 
(p=0.0209). Among these patients, majority were euthyroid 
(63.63%) followed by subclinical hypothyroidism (27.27%) and the 
rest hyperthyroid (9.09%). 
Combined presence of thyroid dysfunction and Anti TPO Ab 
positivity defined as autoimmune thyroid disease (AITD) was found 
at a higher frequency compared with the control group (11.42% vs. 
0%), but failed to achieve statistical significance (p=0.1535). Among 
patients with thyroid dysfunction, the prevalence of AITD was 
28.57% out of which subclinical hypothyroidism occurred at a 
higher frequency compared with hyperthyroidism. 
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6. DISCUSSION 
Several studies have documented an association between 
systemic lupus erythematosus (SLE) and other individual 
autoimmune diseases (AID) such as Sjögren’s syndrome, 
autoimmune hemolytic anemia and antiphospholipid syndrome 
(APS). Patients with SLE might develop other AID that could 
complicate management of SLE by having an adverse impact on 
damage scores and mortality
9
. The association of thyroid disorders 
with SLE has long been the subject of several studies
2, 17, 19, 30-38
. Our 
study aimed to determine whether the increased frequency with 
which thyroid abnormalities occurred in SLE patients was more than 
a chance association. 
In our series of 35 patients with SLE, 40% had thyroid 
dysfunction out of which the prevalence of subclinical 
hypothyroidism (20%) and hyperthyroidism (11.42%) was much 
higher than that noted for the normal background population. 
Euthyroid sick syndrome was found in 8.6% of patients. Thyroid 
autoimmunity (Anti TPO Ab positivity) was found in 31.4% of 
patients out of which thyroid dysfunction was present in 36.36%. 
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The prevalence of autoimmune thyroid disease (11.42%) in our 
study population though higher than in control group, however failed 
to meet statistical significance. 
A number of studies have looked at the prevalence of thyroid 
disease in SLE (Table 18 ).One of the largest studies done looked at 
the prevalence of thyroid disease in 332 patients with SLE admitted 
to hospital in the United States during a five year period
37
. The 
overall prevalence of thyroid disease was 7.5%—6.6% with 
hypothyroidism and 0.9% with hyperthyroidism—which is much 
lower than noted in our study. 
Our study did not have patients with overt thyroid dysfunction 
as compared to several studies which have a prevalence rate over a 
wider range (3%-14%). This could be due to the underlying fact that 
autoimmune thyroiditis constitutes an evolving process which might 
later in the course of the disease present as overt hypothyroidism. 
Subclinical hypothyroidism was found to be much higher in 
frequency, probably reflecting the slow destructive process which is 
pathognomic of autoimmune thyroiditis. 
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TABLE 18 
PREVALENCE OF THYROID DISEASE IN SLE 
POPULATION 
Study No 
of 
cases 
Hypo 
thyroidism 
(%) 
Subclinical 
Hypothyroidism 
     (%) 
Hyper 
thyroidism 
(%) 
Subclinical 
hyperthyroidism 
(%) 
ESS 
(%) 
Miller et 
al
37 
332 6.6 - 0.9 - - 
Pyne et al
30 
300 5.7 - 1.7 - - 
Gao et al
42 
1006 1.69 10.04 1.19 - 9.54 
Kumar et 
al
41 
100 14 12 - 2 8 
Chan et al
40 
69 4.3 13 2.9 2.9 1.5 
Park et al
45 
61 9.5 - 4.8 - 14.3 
Boey et al
34 
129 3.9 - 8.9 - 47.8 
El-Sherif 
WT et al
48 
20 10 10 5 5 20 
Appenzeller 
et al
46 
524 - 11.5 - - - 
PRESENT 
STUDY 
35 - 20 11.42 - 8.6 
 
Pyne et al
30
 had conducted a retrospective analysis of 300 SLE 
cases, wherein the prevalence of overt hypothyroidism was higher 
than in our study group (5.7% vs.0%), while the prevalence of 
hyperthyroidism was lower (1.7% vs.11.42%). Anti TPO Ab 
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positivity was found in 14% and there was no significant difference 
in the frequency with which antimicrosomal antibodies were 
detected between the hyperthyroid and hypothyroid subgroups. On 
the contrary, our study revealed a higher prevalence of subclinical 
hypothyroidism and antimicrosomal antibodies. 
Our study showed the prevalence of subclinical 
hypothyroidism (20%) to be higher than that of the control group. 
Our findings are similar to a large retrospective cohort study done in 
Chinese patients which also had higher prevalence of subclinical 
hypothyroidism (10.04%) compared to other causes of thyroid 
dysfunction
42
. Subclinical hypothyroidism was found to be more 
associated with lupus nephritis. Our conclusions are also supported 
by similar studies done by Kumar et al
41 
and Chan et al
40
 which also 
showed the prevalence of subclinical hypothyroidism to be higher 
than that of overt hypothyroidism. 
Few data are available regarding the association of SLE with 
hyperthyroidism
39
. The prevalence of hyperthyroidism in our 
patients with SLE was 11.42% comparable to 8.9% in a study 
conducted by Boey et al
34
. There are also several case reports 
associating Graves’s disease with SLE but further studies are needed 
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for confirmation of the above association. The prevalence of sick 
euthyroid syndrome also matched the prevalence rates in similar 
studies. 
Several recent studies have addressed the question of whether 
antithyroid antibodies (especially Anti TPO Ab) are present in 
patients with SLE (Table 19). The prevalence of Anti TPO Ab in our 
study group was 31.4% comparable to 32.2%, 46.7%, and 31% in 
studies conducted by Boey et al
34
, Tsai et al
33
 and Ebernard et al
36
 
respectively. An association was also noted between the activity of 
the disease with the presence of antithyroid antibodies
44
. Thyroid 
autoantibodies preceded the occurrence of clinical autoimmune 
thyroid disease in 70% of SLE patients
46
. Antithyroid autoantibodies 
may be good predictors for the detection of Hashimoto's thyroiditis 
developing in SLE
45
. 
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TABLE 19 
PREVALENCE OF THYROID DYSFUNCTION/ 
ANTI TPO Ab /AITD IN SLE PATIENTS 
 
Study 
No of 
cases 
Anti 
thyroid Ab 
(%) 
AITD (%) 
Thyroid 
dysfunction 
(%) 
Kumar et al
41 
100 30 18 36 
Pyne et al
30 
300 14 - 7 
Gao et al
42 
1006 - 2.78 25 
Chan et al
40 
69 23.2 20.3 24.6 
Weetman et al
32 
41 51 24.39 - 
Park et al
45 
61 27 14.3 - 
Appenzeller
46 
524 - 6.1 - 
Present study 35 31.4 11.42 40 
 
Weetman et al
32
 compared the prevalence of thyroid 
autoantibodies and abnormal thyroid-stimulating hormone (TSH) 
levels in 41 SLE patients with age- and sex-matched controls. 
Twenty-one (51%) of the SLE patients had thyroid antibodies 
compared to 11(27%) controls (p<0.05). Ten SLE patients and five 
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controls had elevated TSH levels, usually in association with the 
presence of thyroid autoantibodies. These results suggest that SLE is 
associated with autoimmune thyroiditis and that many patients with 
SLE have minor hypothyroidism, which further supports the results 
of our study. 
The prevalence of autoimmune thyroid disease in our study 
group was 11.42% which is also similar to previous studies (table 
19), although the difference failed to meet statistical significance. 
Hypothyroidism was the predominant manifestation similar to that 
seen in a study by Appenzeller et al
45
. 
Although many international studies have been done, there are 
very few studies to be validated with, in India. In a study conducted 
by Kumar K et al
41 
36% of patients were found to have thyroid 
dysfunction when compared to 8% of controls which was similar to 
our study (40%). All patients were women as against a small 
percentage (18.18%) of males in our study. Disease duration and 
symptomtomatology had no significant correlation with thyroid 
dysfunction or thyroid autoimmunity. Primary hypothyroidism was 
the commonest dysfunction(14%) whereas our study revealed 
subclinical hypothyroidism was more common(20%).The prevalence 
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of thyroid autoimmunity(30% vs.31.4%) and autoimmune thyroid 
disease (18% vs.11.4%)were similar in both the studies. However, 
among the patients with thyroid disease equal prevalence of both 
autoimmune (50%) and non autoimmune disease (50%) were found 
whereas our study showed the prevalence of AITD to be 28.57%. So 
our study conclusions are almost similar except for the higher 
prevalence of subclinical hypothyroidism. 
Pregnant women with SLE will have a high prevalence of 
undiagnosed hypothyroidism and a high prevalence of postpartum 
thyroiditis and women with SLE and thyroid disease will have an 
increased incidence of adverse pregnancy outcomes as compared 
with pregnant women with SLE who do not have thyroid 
disease. The prevalence of preterm delivery was 67% in women with 
thyroid disease and 18% in women who were thyroid disease free
43
. 
Hence the need for appropriate screening tests in SLE population 
and treatment if required. 
Hence, screening for autoimmune thyroid diseases should be 
recommended in everyday clinical practice, in patients with primary 
organ-specific or organ non-specific autoimmune disease. Patients 
with SLE have a higher prevalence of significantly more subclinical 
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hypothyroidism and positive thyroid autoantibodies
46, 48
. Thyroid 
autoantibodies may precede the appearance of clinical 
autoimmune disease. Since symptoms of SLE and thyroid 
disease can be similar, SLE patients should routinely been 
investigated for autoimmune thyroid disease
46
. Subjects at high risk 
(women, positive Ab TPOs) should have thyroid function follow-up 
and appropriate treatment in due course
47
.  
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7. CONCLUSION 
 
 SLE was associated with significant thyroid dysfunction and 
autoimmunity when compared with the normal population 
 
 The prevalence of subclinical hypothyroidism was much 
higher than that of overt hypothyroidism, thus making the 
clinical diagnosis difficult. 
 
 There is a higher frequency of occurrence of hyperthyroidism 
and sick euthyroid syndrome in SLE compared to general 
population though not statistically significant. 
 
 Presence of Anti Thyroid Peroxidase antibodies was more in 
SLE patients suggesting an ongoing destructive autoimmune 
thyroiditis which may later manifest as overt or subclinical 
hypothyroidism 
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 Gender, age and duration of SLE may or may not have a 
significant association with thyroid autoimmunity. 
 
In summary, polyautoimmunity is frequent in SLE, and it is 
influenced by clinical and immunological features. 
Systemic and thyroid autoimmune diseases often overlap with each 
other. Therefore it is clinically important to screen patients 
with systemic autoimmune diseases for the co-existence of thyroid 
disorders. Patients with co-existing thyroid disease and SLE may 
escape clinical detection because of overlapping clinical features. 
Hence serological testing for autoimmune thyroid disease and 
appropriate treatment is warranted in this subset of patients for better 
quality of life. 
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9. PROFORMA 
NAME :                                                                      IP NO  : 
AGE  :        SEX : 
ADDRESS : 
KNOWN CASE / NEWLY DETECTED CASE OF SLE 
HISTORY : 
- Easy fatigability 
- Cold intolerance/ heat intolerance 
- Constipation / diarrhea 
- Weight gain / weight loss 
-  Hair loss 
- Difficulty concentrating and poor memory 
- Breathing difficulty 
- Hoarse voice 
- Menstrual abnormalities 
- Impaired hearing 
OTHER SYMPTOMS OF RELEVANCE 
PAST HISTORY: 
Hypertension / coronary heart disease / Hypothyroidism 
Surgery / irradiation / drug intake 
Chronic kidney disease 
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FAMILY HISTORY  
TREATMENT HISTORY: 
Duration of SLE                                       TREATMENT: 
EXAMINATION 
GENERAL EXAMINATION 
Build / Nourishment 
Waist: hip ratio: 
BMI:                          Ht:           Wt: 
Temperature 
Pallor 
Clubbing 
Lymphadenopathy 
Pedal edema 
Hydration 
Features of hypothyroid / hyperthyroidism: 
Ophthalmology examination: 
Skin changes 
Thyroid: 
BP:                     PR:                    RR: 
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PER ABDOMEN: 
Soft / rigid / Tender / non tender 
Distended 
Organomegaly 
Bowel sounds / Bruit 
CARDIOVASCULAR SYSTEM: 
Heart sounds / Murmurs 
RESPIRATORY SYSTEM: 
Breath sounds / Added sounds 
CNS 
Tremors 
Evidence of peripheral neuropathy 
Focal neurological deficit 
OTHER FINDINGS: 
INVESTIGATIONS:                                                          
     1.  TC, DC, Hb 
     2.  Sugar, urea, creatinine 
            3.  T3, T4, TSH. 
            4.  Urine routine. 
            5.  Anti TPO Ab 
 
OTHER RELEVANT INVESTIGATIONS 
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MASTER CHART 
NO AGE SEX DURATION SYMPTOMS T3 T4 TSH TPO INTERPRETATION AUTOIMMUNE 
THYROIDITIS 
1 30 F NEW PRESENT 1.6 128.1 6.3 9.89 SUBCLINICAL  
HYPOTHYROIDISM 
---- 
2 29 F 5 YEARS PRESENT 1.1 83.4 7.4 114.60 SUBCLINICAL  
HYPOTHYROIDISM 
+ 
3 24 F 6 MONTHS ABSENT 4.8 188.6 0.04 35.91 HYPERTHYROIDISM + 
4 28 F NEW PRESENT 1.3 126.3 0.9 7.63 EUTHYROID ----- 
5 24 F 7 YEARS ABSENT 1.2 60.8 2 16.34 EUTHYROID ----- 
6 52 F 6 MONTHS ABSENT 1.7 112.30 1.58 31.88 EUTHYROID ----- 
7 22 M 3 YEARS ABSENT 0.8 109.74 5.47 12.29 SUBCLINICAL 
HYPOTHYROIDISM 
----- 
8 24 F NEW ABSENT 1.2 123.45 17.71 72.60 SUBCLINICAL 
HYPOTHYROIDISM 
+ 
9 33 F 4 MONTHS PRESENT 0.8 102.41 3.47 17.68 EUTHYROID ----- 
10 22 F 1 MONTH PRESENT 3 177.1 0.02 27.14 HYPERTHYROIDISM ----- 
11 39 F 6 MONTHS PRESENT 2.3 83.8 0.34 13.8 HYPERTHYROIDISM 
(T3) 
----- 
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12 32 F 1 YEAR PRESENT 1.1 102.0 2.1 17.21 EUTHYROID ----- 
13 30 F 1 YEAR PRESENT 0.9 88.7 2.7 67.78 EUTHYROID + 
14 23 F 4 YEARS ABSENT 1.2 130.4 1.6 19.59 EUTHYROID ----- 
15 21 F 1 YEAR ABSENT 0.9 83.8 1 86.21 EUTHYROID + 
16 20 F 2 YEARS ABSENT 0.8 67 2.6 11.18 EUTHYROID ----- 
17 23 F 2 MONTHS PRESENT 0.8 100.3 3.09 338.90 EUTHYROID + 
18 35 F NEW ABSENT 1.05 102 1.02 12.51 EUTHYROID ------ 
19 36 F 6 MONTHS ABSENT 2 129 1 18.26 EUTHYROID ----- 
20 19 F 4 YEARS ABSENT 1.3 211 0.09 28.82 HYPERTHYROIDISM  
(T4) 
----- 
21 19 F 1 YEAR PRESENT 1.7 118 0.7 76.03 EUTHYROID + 
22 24 F 6 MONTHS PRESENT 1.6 91 3.1 145.3 EUTHYROID + 
23 21 F NEW PRESENT 1.2 99 6.3 24.58 SUBCLINICAL 
HYPOTHYROIDISM 
---- 
24 23 F NEW ABSENT 0.9 107 1.6 13 EUTHYROID ------ 
25 16 M 3 MONTHS PRESENT 1 120 6.2 18 SUBCLINICAL 
HYPOTHYROIDISM 
------ 
26 45 F 8 YEARS ABSENT 0.53 80.4 1.87 14.49 NON THYROIDAL 
ILLNESS 
---- 
27 17 F 1 MONTH PRESENT 1.6 122.60 3.54 349.40 EUTHYROID + 
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28 21 F NEW PRESENT 0.9 85.9 3.76 25.25 EUTHYROID ----- 
29 17 M 2 YEARS ABSENT 0.6 109.1 0.741 26.17 NON THYROIDAL 
ILLNESS 
----- 
30 24 F NEW ABSENT 0.48 59.1 3.51 13.67 NON THYROIDAL 
ILLNESS 
------ 
31 26 F NEW PRESENT 0.9 62.80 2 24.60 EUTHYROID ------ 
32 32 F 4 YEARS ABSENT 1.1 122.40 3.2 18.78 EUTHYROID ------ 
33 22 F 8 MONTHS ABSENT 1.7 92.33 1.6 56.72 EUTHYROID + 
34 26 F 2 YEARS ABSENT 1.6 110.58 0.8 12.68 EUTHYROID ------ 
35 20 F NEW ABSENT 1.7 95.3 19.20 600 SUBCLINICAL 
HYPOTHYROIDISM 
+ 
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AGE AND SEX MATCHED CONTROLS 
NO AGE SEX T3 T4 TSH TPO INTERPRETATION AUTOIMMUNE 
DISEASE 
1 15 M 1.4 92.1 2.08 22.59 EUTHYROID -- 
2 18 M 1.6 108.2 3.45 32.24 EUTHYROID -- 
3 18 M 1.2 102.4 3.35 11.67 EUTHYROID -- 
4 38 F 1.16 69.5 3.65 18.49 EUTHYROID -- 
5 34 F 1.54 102.4 5.10 10.66 EUTHYROID -- 
6 16 F 1.12 75.8 1.77 75.58 EUTHYROID + 
7 29 F 1.4 96.3 2.12 9.82 EUTHYROID -- 
8 35 F 1.02 89.8 1.53 12.29 EUTHYROID -- 
9 30 F 0.42 104.6 7.84 31.22 NON THYROID 
ILLNESS 
-- 
10 30 F 1.56 90.9 3.45 33.48 EUTHYROID -- 
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11 40 F 1.32 106 2.75 28.22 EUTHYROID -- 
12 35 F 1.2 96.40 3.10 24.78 EUTHYROID -- 
13 15 F 0.96 109.8 3.31 8.23 EUTHYROID -- 
14 27 F 1.43 115.6 3.71 6.13 EUTHYROID -- 
15 26 F 1.2 76.9 4.23 8.29 EUTHYROID -- 
16 32 F 1.21 83 2.05 9.05 EUTHYROID -- 
17 32 F 0.9 91 2.81 5.62 EUTHYROID -- 
18 28 F 1.6 126.86 2.64 11.34 EUTHYROID -- 
19 34 F 1.4 110.24 3.18 21.34 EUTHYROID -- 
20 22 F 1.2 76.20 1.54 8.82 EUTHYROID -- 
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